Form 4: PACS Group CEO Jason Murray Granted 234,397 RSUs

PACS Group, Inc. Co-Founder, CEO, and Chairman Jason Hulse Murray was granted 234,397 restricted stock units (RSUs) on March 24, 2026, which will vest over three years.

Summary

• Jason Hulse Murray, Co-Founder, CEO, Chairman, Director, and 10% Owner of PACS Group, Inc., was granted 234,397 Restricted Stock Units (RSUs).
• The RSUs were granted on March 24, 2026, at a price of $0 per unit.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting.
• The RSUs will vest in substantially equal annual installments on the first, second, and third anniversaries of the grant date (March 24, 2026).
• Vesting is contingent upon Mr. Murray's continued service to the company through each applicable vesting date.
• Following this transaction, Mr. Murray beneficially owns 55,081,532 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it reinforces the CEO's long-term commitment to PACS Group through equity alignment, which is generally favorable for shareholder value.

Positives

• The grant of RSUs aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule incentivizes continued service and performance from a key executive.

Negatives

• Potential for future dilution of existing shares upon the vesting and conversion of RSUs into common stock.

Risks

• The Restricted Stock Units are subject to forfeiture if the reporting person's service to the company ceases before the applicable vesting dates.

Future Outlook

The RSUs are expected to vest in three annual installments, contingent on continued service, indicating a future commitment from the CEO and a structured approach to long-term executive incentives.

Industry Context

StockSavvy.ai notes that equity compensation, such as RSU grants with multi-year vesting schedules, is a standard practice across industries to align executive incentives with long-term company performance and shareholder interests. This grant to a key executive like the CEO is typical for retaining top talent and fostering commitment within the healthcare services sector.

Comparison to Industry Standards

• The grant of RSUs with a three-year vesting schedule is a common practice in executive compensation packages across publicly traded companies, comparable to practices seen at peers in the healthcare services or long-term care industry, such as Ensign Group (ENSG) or Genesis Healthcare (GEN).
• The $0 grant price for RSUs is standard, as these units represent a right to receive shares upon vesting, rather than a direct purchase.

Related Party Transactions

• Grant of 234,397 Restricted Stock Units (RSUs) to Jason Hulse Murray, the Co-Founder, CEO, Chairman, Director, and 10% Owner of PACS Group, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential long-term value creation through incentivized management; minor future dilution upon vesting of RSUs.
• Employees: May signal stability in leadership and a commitment to long-term company strategy.

Next Steps

• First annual vesting installment of the RSUs on the anniversary of March 24, 2026.
• Second annual vesting installment of the RSUs on the second anniversary of March 24, 2026.
• Third annual vesting installment of the RSUs on the third anniversary of March 24, 2026.

Key Dates

Recommendation

This Form 4 filing reports a standard equity compensation grant to the CEO, which is a routine event and does not provide new information that would significantly alter the investment thesis for PACS Group, Inc. It primarily serves to align executive incentives with long-term shareholder value, which is generally a positive but not a catalyst for a change in recommendation.

Keywords

PACS Group, Jason Hulse Murray, Form 4, Restricted Stock Units, RSU grant, insider transaction, equity compensation, CEO compensation, director compensation